Schlusskurs
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
19.934 ARS | +2,53 % |
|
+8,92 % | +96,73 % |
07.06. | Aktien New York Schluss: Weitere Rekorde ohne viel Bewegung | DP |
07.06. | AKTIEN IM FOKUS 2/Abnehm-Boom: Rally bei Eli Lilly und Novo Nordisk geht weiter | DP |
Kurzporträt
- Endokrinologie (57,7%): Produkte zur Behandlung von Osteoporose, Diabetes und Wachstumsstörungen;
- Onkologie (19,5%);
- Immunologische Erkrankungen (11,1%);
- Neurologie (8,4%): hauptsächlich Medikamente zur Behandlung von Depressionen und Schizophrenie;
- Sonstige (3,3%).
Der Nettoumsatz verteilt sich geografisch wie folgt: Vereinigte Staaten (63,9%), Europa (18,1%), Japan (4,9%), China (4,5%) und Sonstige (8,6%).
Mitarbeiterzahl: 43 000
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Human Pharmaceutical Products
100,0
%
| 28 541 | 100,0 % | 34 124 | 100,0 % | +19,56 % |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
63,9
%
| 18 190 | 63,7 % | 21 791 | 63,9 % | +19,80 % |
Europe
18,1
%
| 4 299 | 15,1 % | 6 175 | 18,1 % | +43,62 % |
Other Foreign Countries
8,6
%
| 2 852 | 10,0 % | 2 946 | 8,6 % | +3,30 % |
Japan
4,9
%
| 1 747 | 6,1 % | 1 673 | 4,9 % | -4,28 % |
China
4,5
%
| 1 453 | 5,1 % | 1 540 | 4,5 % | +5,98 % |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01.01.96 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16.10.23 |
Alonzo Weems
CMP | Compliance Officer | - | 01.01.97 |
Chief Tech/Sci/R&D Officer | 50 | 01.01.18 | |
Diogo Rau
CTO | Chief Tech/Sci/R&D Officer | - | 17.05.21 |
Johna Norton
PRN | Corporate Officer/Principal | 57 | 01.04.17 |
Corporate Officer/Principal | - | 01.01.05 | |
Ilya Yuffa
PRN | Corporate Officer/Principal | 49 | - |
- | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Director/Board Member | 63 | 25.01.21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01.04.09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01.01.05 |
Juan Luciano
BRD | Director/Board Member | 62 | 01.02.16 |
William Kaelin
BRD | Director/Board Member | 66 | 04.06.12 |
David Ricks
CEO | Chief Executive Officer | 56 | 01.01.96 |
Jamere Jackson
BRD | Director/Board Member | 54 | 01.10.16 |
Director/Board Member | 52 | 12.12.11 | |
Marschall Runge
BRD | Director/Board Member | 69 | 01.09.13 |
Karen Walker
BRD | Director/Board Member | 62 | 01.12.18 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 950 770 386 | 948 828 714 ( 99,80 %) | 365 000 ( 0,0384 %) | 99,80 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
IMMUNOCORE HOLDINGS PLC 6,25% | 2 548 145 | 6,25% | 147 792 410 $ |
8 084 411 | 6,83% | 50 293 848 $ | |
PROQR THERAPEUTICS N.V. 16,55% | 13 371 562 | 16,55% | 26 208 262 $ |
4 000 000 | 9,40% | 20 920 000 $ | |
21 776 804 | 7,60% | 11 332 213 $ | |
AC IMMUNE SA 3,64% | 3 615 328 | 3,64% | 8 279 101 $ |
125 405 | 1,81% | 1 218 937 $ |
Unternehmenskontakt
![Straße Eli Lilly and Company(LLY)](https://cdn.zonebourse.com/static/address/119075604.png)
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
ELI Lilly & Company (India) Pvt Ltd.
![]() ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology ELI Lilly & Company (India) Pvt Ltd. manufactures and markets pharmaceutical products. The firm's products treat diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. The company was founded in 1993 and is headquartered in Gurgaon, India. |
Pharmaceuticals: Major
|
Eli Lilly Services India Pvt Ltd.
![]() Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Services India Pvt Ltd. is an Indian company that discovers, develops, manufactures and sells pharmaceutical products. The company is based in Bangalore, India and was founded in 2015. |
Pharmaceuticals: Major
|
Eli Lilly Export SA (Switzerland)
![]() Eli Lilly Export SA (Switzerland) Medical DistributorsDistribution Services Part of Eli Lilly & Co., Eli Lilly Export SA is a pharmaceutical company based in Vernier, Switzerland. The Swiss company combines care with research to develop innovative solutions for a better life worldwide. |
Medical Distributors
|
Kinsale Financial Services
| |
Lilly Nederland Finance BV
![]() Lilly Nederland Finance BV Miscellaneous Commercial ServicesCommercial Services Part of Eli Lilly & Co., Lilly Nederland Finance BV leases non-financial intangible assets. The company is based in Utrecht, Netherlands. |
Miscellaneous Commercial Services
|
Eli Lilly SA
![]() Eli Lilly SA Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The company is based in Vernier, Switzerland. |
Pharmaceuticals: Major
|
Eli Lilly (Suisse) SA
| |
Lilly Global Nederland Holdings BV
![]() Lilly Global Nederland Holdings BV Financial ConglomeratesFinance Part of Eli Lilly & Co., Lilly Global Nederland Holdings BV functions as an investment holding Dutch company. The company is based in Utrecht, Netherlands. |
Financial Conglomerates
|
Eli Lilly Vostok SA
|
Sektor
Umsatz je Region
![Analystenschätzungen](/images/consensus_flch.gif)
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+40,95 % | 632 Mrd. | |
-6,16 % | 354 Mrd. | |
+19,86 % | 331 Mrd. | |
+9,32 % | 299 Mrd. | |
+18,45 % | 248 Mrd. | |
+11,88 % | 216 Mrd. | |
-0,78 % | 219 Mrd. | |
+5,90 % | 164 Mrd. | |
-0,73 % | 162 Mrd. |
- Börse
- Aktien
- 858560 Aktie
- LLY Aktie
- Unternehmen Eli Lilly and Company